What is Lexaria Bioscience Corp. Warrant's earnings per share (EPS)?

Lexaria Bioscience Corp. Warrant (LEXXW) reported diluted earnings per share of -$0.66 for fiscal year 2025. This represents a -40.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lexaria Bioscience Corp. Warrant (LEXXW) Financials

LEXXW

Trailing 12 months to February 28, 2026

Revenue $368K -30.0% YoY

Net Income -$9.5M -1.6% YoY

EPS (Diluted) -$0.66 FY2025 annual

Free Cash Flow -$9.4M -26.4% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Feb 28, 2026 Reported Apr 13, 2026 Currency USD FYE August

Newest figures come from the 10-Q for Q2 FY2026, filed Apr 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LEXXW SEC filings page.

Lexaria Bioscience Corp. Warrant (LEXXW) reported $368K in revenue over the twelve months to Feb 28, 2026, down 30.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LEXXW FY2025 2026-08-26

Lexaria’s development-stage model pairs near-total gross margins with R&D-led cash consumption and recurring external financing.

In FY2025, R&D spending reached $8.2M while operating cash flow was -$10.5M, linking the company’s cash need to development activity more than product delivery costs. Free cash flow was -$10.5M against only $25K of capital expenditures, so nearly all reported cash consumption came from operating the program rather than building fixed assets.

The margin structure is unusual: gross margin was 99.6% in FY2025, but operating margin was -16.8%; most economic friction sits below gross profit. R&D exceeded revenue by more than 11 times, creating a development-stage cost structure rather than a scaled commercial model.

The business relied partly on external financing: FY2025 financing cash flow of $6.0M offset only part of operating cash flow of -$10.5M. Leverage increased as debt-to-equity rose to 0.5x from 0.2x in FY2024, indicating a less conservative financing posture.

Financial Health Signals

Financial health score not available

Lexaria Bioscience Corp. Warrant does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/8

Lexaria Bioscience Corp. Warrant passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Lexaria Bioscience Corp. Warrant reported a net loss of $11.9M while operations used $10.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$20K

YoY-88.5%

5Y CAGR-36.4%

10Y CAGR+2.8%

Lexaria Bioscience Corp. Warrant generated $20K in revenue in Q2 2026. This represents a decrease of 88.5% from the same quarter a year earlier.

Net Income

-$1.4M

YoY+46.6%

QoQ+9.1%

Lexaria Bioscience Corp. Warrant reported -$1.4M in net income in Q2 2026. This represents an increase of 46.6% from the same quarter a year earlier. Against the prior quarter it is up 9.1%.

EPS (Diluted)

-$0.06

YoY+60.0%

QoQ+14.3%

Lexaria Bioscience Corp. Warrant earned -$0.06 per diluted share (EPS) in Q2 2026. This represents an increase of 60.0% from the same quarter a year earlier. Against the prior quarter it is up 14.3%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$2.2M

YoY-47.2%

QoQ-124.0%

Lexaria Bioscience Corp. Warrant recorded an outflow of $2.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 47.2% from the same quarter a year earlier. Against the prior quarter it is down 124.0%.

Cash & Debt

$5.1M

YoY-21.5%

QoQ+18.6%

5Y CAGR-11.4%

10Y CAGR+62.3%

Lexaria Bioscience Corp. Warrant held $5.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

25M

YoY+41.2%

QoQ-0.4%

5Y CAGR+37.2%

10Y CAGR-5.7%

Lexaria Bioscience Corp. Warrant had 25M shares outstanding in Q2 2026. This represents an increase of 41.2% from the same quarter a year earlier. Against the prior quarter it is down 0.4%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

100.0%

YoY0.0pp

Lexaria Bioscience Corp. Warrant's gross margin was 100.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. That is unchanged from the same quarter a year earlier.

Return on Equity

-22.0%

YoY+16.0pp

QoQ+10.5pp

5Y change-25.3pp

10Y change+76.1pp

Lexaria Bioscience Corp. Warrant's ROE was -22.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 16.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.5 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$475K

YoY-71.8%

QoQ-29.2%

5Y CAGR+21.9%

10Y CAGR+52.8%

Lexaria Bioscience Corp. Warrant invested $475K in research and development in Q2 2026. This represents a decrease of 71.8% from the same quarter a year earlier. Against the prior quarter it is down 29.2%.

Capital Expenditures

$41K

YoY+4081500.0%

Lexaria Bioscience Corp. Warrant invested $41K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 4081500.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

LEXXW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LEXXW quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY14	FY13	FY11
Revenue	$368K	$706K+52.0%	$464K+105.2%	$226K-11.4%	$255K-64.7%	$723K+129.6%	$315K+41.4%	$223K-48.6%	$433K+580.9%	$64K+56.3%	$41K+177.0%	$15K	$0	N/A	N/A	N/A
Cost of Revenue	$0	$3K-43.6%	$5K-84.7%	$32K-56.2%	$72K-59.0%	$175K+76.4%	$99K+334.1%	$23K-9.1%	$25K-15.3%	$30K-34.8%	$46K+52.6%	$30K	$0	$795K+1.5%	$783K	$668K
Gross Profit	$368K	$703K+53.1%	$459K+136.0%	$195K+6.1%	$184K-66.5%	$547K+154.1%	$215K+7.9%	$200K-51.1%	$408K+1104.2%	$34K+792.0%	-$5K+67.7%	-$15K	$0	$302K-47.4%	$574K	$466K
R&D Expenses	$5.7M	$8.2M+249.0%	$2.4M-35.6%	$3.7M+99.0%	$1.8M+45.9%	$1.3M+226.3%	$387K-30.3%	$556K+12.8%	$493K+809.6%	$54K+500.5%	$9K-93.8%	$146K	$0	N/A	N/A	N/A
SG&A Expenses	$4.1M	$4.3M+12.8%	$3.9M+25.8%	$3.1M-38.3%	$5.0M-0.2%	$5.0M+25.0%	$4.0M+1238.2%	$297K+36.6%	$218K+67.8%	$130K-3.0%	$134K+609.8%	$19K+62.0%	$12K	$7K+127.7%	$3K	$5K
Operating Income	-$9.5M	-$11.9M-106.5%	-$5.8M+12.0%	-$6.5M+1.3%	-$6.6M-16.4%	-$5.7M	N/A	N/A	N/A	N/A	-$1.3M+35.6%	-$2.0M-27.2%	-$1.6M	N/A	N/A	N/A
EBITDA	N/A	-$11.8M-107.1%	-$5.7M+10.6%	-$6.4M+2.0%	-$6.5M-16.9%	-$5.6M	N/A	N/A	N/A	N/A	-$1.3M+35.6%	-$2.0M	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	$8K	$0	N/A	N/A	N/A	N/A	N/A	$6K+167.3%	$2K-92.9%	$32K-81.0%	$166K	$267K+12.5%	$238K	$224K
Income Tax	N/A	N/A	N/A	N/A	$0-100.0%	$6K+162.7%	$2K-86.9%	$18K	$0	$0	$0	N/A	N/A	N/A	N/A	N/A
Net Income	-$9.5M	-$11.9M-105.4%	-$5.8M+13.0%	-$6.7M+8.3%	-$7.3M-80.5%	-$4.0M+1.4%	-$4.1M-199.6%	$4.1M-37.9%	$6.6M+442.1%	-$1.9M-51.1%	-$1.3M+35.6%	-$2.0M-27.2%	-$1.6M	N/A	N/A	-$538K
EPS (Diluted)	—	-$0.66-40.4%	-$0.47	-$1.01	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$0.04
Diluted Shares (Avg)	N/A	18M+45.3%	12M	7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	14M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$20K-88.5%	$0-100.0%	$174K+107.1%	$174K+107.1%	$174K+20.0%	$184K+21.6%	$84K+173.3%	$84K+8.1%
Cost of Revenue	$0	$0-100.0%	$0	$0	$0	$3K-43.6%	$0	$0-100.0%
Gross Profit	$20K-88.5%	$0-100.0%	$174K+107.1%	$174K+107.1%	$174K+20.0%	$181K+23.7%	$84K+173.3%	$84K+29.3%
R&D Expenses	$475K-71.8%	$671K-65.6%	$1.9M+94.6%	$2.7M+374.2%	$1.7M+585.9%	$2.0M+240.0%	$967K+93.3%	$573K-65.1%
SG&A Expenses	$997K-19.6%	$902K-1.8%	$980K-25.7%	$1.2M-3.7%	$1.2M+118.4%	$919K+29.2%	$1.3M+104.8%	$1.3M+51.9%
Operating Income	-$1.5M+47.2%	-$1.6M+41.5%	-$2.7M-22.0%	-$3.8M-115.2%	-$2.8M-311.8%	-$2.7M-136.2%	-$2.2M-97.7%	-$1.7M+27.4%
EBITDA	N/A	-$1.6M+41.8%	N/A	N/A	N/A	-$2.7M-141.5%	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%
Income Tax	$3K	$2K	N/A	N/A	$0	$0	N/A	N/A
Net Income	-$1.4M+46.6%	-$1.6M+41.0%	-$2.7M-23.4%	-$3.8M-112.7%	-$2.7M-317.7%	-$2.7M-129.3%	-$2.2M-76.3%	-$1.8M+24.9%
EPS (Diluted)	-$0.06+60.0%	-$0.07+56.3%	N/A	-$0.21-61.5%	-$0.15	-$0.16	N/A	-$0.13
Diluted Shares (Avg)	24M+39.6%	21M+28.2%	N/A	18M+32.1%	18M	17M	N/A	14M

Not reported in any period shown, so not listed: EPS (Basic).

LEXXW Balance Sheet

LEXXW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY14	FY13	FY11
Total Assets	$4.2M-52.9%	$8.9M+187.5%	$3.1M-60.6%	$7.8M-41.0%	$13.3M+369.1%	$2.8M+5.7%	$2.7M+10.0%	$2.4M-15.0%	$2.9M+404.8%	$567K-20.4%	$712K-73.0%	$2.6M	$3.6M-9.3%	$3.9M	$4.2M
Current Assets	$3.5M-56.1%	$7.9M+267.1%	$2.2M-69.2%	$7.0M-43.9%	$12.4M+546.1%	$1.9M+5.9%	$1.8M-20.4%	$2.3M-18.3%	$2.8M+448.0%	$510K-24.4%	$675K-73.7%	$2.6M	$165K-42.2%	$285K	$323K
Cash & Equivalents	$1.8M-72.3%	$6.5M+380.7%	$1.4M-76.7%	$5.8M-46.8%	$10.9M+743.9%	$1.3M+0.7%	$1.3M-25.6%	$1.7M-31.8%	$2.5M+2612.1%	$93K-64.1%	$260K-63.0%	$703K	$125K+221.5%	$39K	$140K
Short-Term Investments	$143K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Inventory	N/A	N/A	$0-100.0%	$38K+29.6%	$30K-74.6%	$117K-8.3%	$127K+46.0%	$87K+29.9%	$67K-50.1%	$135K-19.8%	$168K	$0	N/A	N/A	N/A
Accounts Receivable	$368K+138.5%	$154K+21.9%	$127K-37.2%	$202K-41.1%	$342K+9.1%	$314K+14.9%	$273K+2.8%	$266K+486.7%	$45K-65.4%	$131K+317.7%	$31K-67.6%	$97K	$131K-45.5%	$240K	$176K
Long-Term Investments	$349K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.6M+30.1%	$1.2M+199.3%	$404K+100.5%	$201K-0.9%	$203K-41.2%	$346K+87.5%	$185K+322.8%	$44K-52.7%	$92K-69.3%	$301K+445.3%	$55K-94.0%	$918K	$1.5M-5.0%	$1.6M	$1.7M
Current Liabilities	$1.5M+35.8%	$1.1M+310.6%	$268K+38.0%	$194K+26.6%	$153K-32.2%	$226K+22.4%	$185K+322.8%	$44K-52.7%	$92K	N/A	$55K-94.0%	$918K	$1.5M-5.2%	$1.6M	$1.7M
Non-Current Liabilities	$79K-27.8%	$109K-19.7%	$136K+1739.9%	$7K-85.2%	$50K-58.4%	$120K	$0	$0	$0+100.0%	-$133K	$0	$0	$59K0.0%	$59K	$0
Total Equity	$3.0M-62.8%	$8.0M+164.0%	$3.0M-61.7%	$7.9M-39.2%	$13.1M+426.3%	$2.5M-0.3%	$2.5M+4.3%	$2.4M-13.7%	$2.8M+940.4%	$266K-65.6%	$772K-55.0%	$1.7M	$2.0M-12.2%	$2.3M	$2.6M
Retained Earnings	-$63.5M-23.1%	-$51.6M-12.7%	-$45.8M-17.0%	-$39.1M-22.8%	-$31.8M-14.5%	-$27.8M-16.5%	-$23.9M-20.7%	-$19.8M-50.1%	-$13.2M-16.5%	-$11.3M-12.0%	-$10.1M-21.3%	-$8.3M	-$5.2M-6.9%	-$4.8M	-$4.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$6.5M-25.2%	$6.1M-38.2%	$4.2M-52.9%	$6.7M-32.7%	$8.7M+36.6%	$9.8M+170.0%	$8.9M+187.5%	$10.0M+91.2%
Current Assets	$5.8M-25.3%	$5.4M-39.2%	$3.5M-56.1%	$5.8M-36.1%	$7.7M+42.6%	$8.8M+227.7%	$7.9M+267.1%	$9.1M+114.7%
Cash & Equivalents	$5.1M-21.5%	$4.3M-46.8%	$1.8M-72.3%	$4.6M-45.6%	$6.5M+38.1%	$8.1M+313.4%	$6.5M+380.7%	$8.5M+167.4%
Accounts Receivable	$42K-87.3%	$88K-66.6%	$368K+138.5%	$358K+71.8%	$331K-7.3%	$263K-50.7%	$154K+21.9%	$208K+21.0%
Total Liabilities	$277K-85.5%	$1.5M+282.1%	$1.6M+30.1%	$1.6M+480.3%	$1.9M+838.7%	$400K+57.3%	$1.2M+199.3%	$271K-77.4%
Current Liabilities	$215K-88.2%	$1.5M+389.1%	$1.5M+35.8%	$1.5M+853.6%	$1.8M+2130.2%	$298K+139.2%	$1.1M+310.6%	$156K-85.2%
Non-Current Liabilities	$62K-34.0%	$71K-30.5%	$79K-27.8%	$87K-24.8%	$94K-22.9%	$102K-21.3%	$109K-19.7%	$115K-19.1%
Total Equity	$6.6M-7.6%	$4.9M-49.7%	$3.0M-62.8%	$5.6M-45.2%	$7.1M+9.6%	$9.8M+161.2%	$8.0M+164.0%	$10.1M+130.3%
Retained Earnings	-$66.5M-16.7%	-$65.1M-19.9%	-$63.5M-23.1%	-$60.8M-23.1%	-$57.0M-19.7%	-$54.3M-15.6%	-$51.6M-12.7%	-$49.4M-10.9%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.

LEXXW Cash Flow Statement

LEXXW quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY14	FY13	FY11
Operating Cash Flow	-$9.4M	-$10.5M-110.7%	-$5.0M+15.7%	-$5.9M-20.5%	-$4.9M-22.3%	-$4.0M-52.3%	-$2.6M+12.9%	-$3.0M-19.4%	-$2.5M-62.9%	-$1.5M-133.9%	-$661K+56.0%	-$1.5M-191.0%	-$516K	$321K+136.1%	$136K	$110K
Depreciation & Amortization	N/A	$51K+20.7%	$42K-70.8%	$145K+41.5%	$103K-8.1%	$112K-6.5%	$120K+84.0%	$65K+1525.6%	$4K+69.5%	$2K+280.8%	$619	$0	N/A	N/A	$0	$425
Stock-Based Compensation	N/A	$859K+74.6%	$492K+188.9%	$170K-77.4%	$753K+83.6%	$410K-64.0%	$1.1M+81.8%	$627K-75.9%	$2.6M+2202.0%	$113K-7.4%	$122K-52.3%	$256K+164.0%	$97K	$21K+87.7%	$11K	$180K
Capital Expenditures	$41K	$25K-42.7%	$43K+27.5%	$34K-31.4%	$49K	N/A	$0-100.0%	$646K	N/A	$0-100.0%	$3K	$0	N/A	N/A	N/A	N/A
Free Cash Flow	-$9.4M	-$10.5M-109.4%	-$5.0M+15.4%	-$5.9M-20.0%	-$4.9M	N/A	-$2.6M+28.3%	-$3.7M	N/A	-$1.5M-132.8%	-$664K+55.8%	-$1.5M	N/A	N/A	N/A	N/A
Investing Cash Flow	-$236K	-$243K-28.9%	-$189K-11.2%	-$170K+6.1%	-$181K-193.2%	$194K+822.3%	-$27K+96.5%	-$769K-395.0%	-$155K-1502.2%	-$10K+51.8%	-$20K-102.9%	$685K+997.7%	-$76K	-$71K+74.2%	-$274K	-$1.0M
Financing Cash Flow	$8.2M	$6.0M-41.4%	$10.3M+548.9%	$1.6M+3664.4%	-$45K-100.3%	$13.4M+405.6%	$2.7M-20.4%	$3.3M+78.5%	$1.9M-53.3%	$4.0M+676.9%	$514K+37.8%	$373K-69.6%	$1.2M	-$365K-227.1%	$288K	$861K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$2.2M-44.5%	-$984K+63.9%	-$2.6M-39.7%	-$3.6M-183.1%	-$1.5M-141.7%	-$2.7M-130.7%	-$1.9M-16.6%	-$1.3M+29.1%
Depreciation & Amortization	N/A	$12K+37.5%	N/A	N/A	N/A	$9K-69.7%	N/A	N/A
Stock-Based Compensation	N/A	$75K-24.7%	N/A	N/A	N/A	$99K+84.3%	N/A	$342K+319.6%
Capital Expenditures	$41K+4081500.0%	$0-100.0%	$1-100.0%	-$1	$1	$25K	$43K	$0
Free Cash Flow	-$2.2M-47.2%	-$984K+64.2%	-$2.6M-36.6%	-$3.6M-183.1%	-$1.5M-141.7%	-$2.8M-132.8%	-$1.9M-19.3%	-$1.3M+29.1%
Investing Cash Flow	-$54K-93.3%	-$5K+86.5%	-$158K-126.9%	-$19K+11.6%	-$28K+51.1%	-$38K+5.6%	-$70K-1.7%	-$22K+34.6%
Financing Cash Flow	$3.0M+25873.2%	$3.5M-20.1%	$0	$1.7M-66.5%	$12K-99.7%	$4.3M+138.8%	$0+100.0%	$5.0M+194.7%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

LEXXW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LEXXW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY14	FY13	FY11
Gross Margin	99.6%+0.6pp	99.0%+12.9pp	86.1%+14.2pp	71.9%-3.9pp	75.7%+7.3pp	68.4%-21.3pp	89.7%-4.5pp	94.2%+40.9pp	53.3%+65.3pp	-12.0%	-103.3%	N/A	N/A	N/A	N/A
Operating Margin	-1683.0%	-1239.2%	-2888.5%	-2591.7%	-786.9%	N/A	N/A	N/A	N/A	-3136.8%	-13489.8%	N/A	N/A	N/A	N/A
Net Margin	-1686.0%	-1248.3%	-2946.4%	-2846.3%	-557.2%	-1297.6%	1841.8%	1523.2%	-3031.9%	-3136.8%	-13489.8%	N/A	N/A	N/A	N/A
Return on Equity	-398.1%-326.0pp	-72.1%+146.8pp	-218.9%-127.5pp	-91.5%-60.6pp	-30.8%+133.7pp	-164.5%-329.2pp	164.6%-111.8pp	276.4%+346.1pp	-69.7%+410.4pp	-480.1%-223.3pp	-256.8%-165.9pp	-90.8%	N/A	N/A	-21.1%
Return on Assets	-285.1%-219.7pp	-65.3%+150.8pp	-216.1%-123.3pp	-92.8%-62.4pp	-30.3%+114.1pp	-144.4%-297.7pp	153.3%-118.1pp	271.4%+338.9pp	-67.5%+158.0pp	-225.4%+53.2pp	-278.7%-219.5pp	-59.2%	N/A	N/A	-12.7%
Current Ratio	2.32-4.9x	7.18-0.9x	8.03-27.9x	35.96-45.2x	81.18+72.7x	8.53-1.3x	9.86-42.5x	52.34+22.1x	30.27	N/A	12.24+9.4x	2.80	0.11-0.1x	0.18	0.19
Debt-to-Equity	0.53+0.4x	0.150.0x	0.13+0.1x	0.030.0x	0.02-0.1x	0.14+0.1x	0.07+0.1x	0.020.0x	0.03-1.1x	1.13+1.1x	0.07-0.5x	0.53	0.76+0.1x	0.70	0.66
Asset Turnover	0.17+0.1x	0.050.0x	0.070.0x	0.030.0x	0.05-0.1x	0.110.0x	0.08-0.1x	0.18+0.2x	0.020.0x	0.07+0.1x	0.020.0x	0.00	N/A	N/A	N/A
FCF Margin	-1483.9%	-1077.4%	-2614.8%	-1929.8%	N/A	-831.9%	-1640.4%	N/A	-2429.2%	-1630.6%	-10209.7%	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	100.0%0.0pp	N/A	100.0%0.0pp	100.0%0.0pp	100.0%0.0pp	98.5%+1.7pp	100.0%0.0pp	100.0%+16.4pp
Operating Margin	-7259.5%	N/A	-1545.2%	-2155.4%	-1581.0%	-1463.0%	-2622.7%	-2074.9%
Net Margin	-7249.9%	N/A	-1549.3%	-2177.6%	-1559.3%	-1470.0%	-2600.9%	-2121.1%
Return on Equity	-22.0%+16.0pp	-32.5%-4.8pp	-90.2%-63.0pp	-68.3%-50.6pp	-38.0%-28.0pp	-27.7%+3.8pp	-27.2%+13.5pp	-17.6%+36.4pp
Return on Assets	-22.4%+8.9pp	-26.4%+1.3pp	-64.6%-39.9pp	-56.2%-38.4pp	-31.3%-21.0pp	-27.6%+4.9pp	-24.6%+15.5pp	-17.8%+27.5pp
Current Ratio	26.88+22.6x	3.68-26.0x	2.32-4.9x	3.90-54.4x	4.24-62.1x	29.64+8.0x	7.18-0.9x	58.27+54.3x
Debt-to-Equity	0.04-0.2x	0.31+0.3x	0.53+0.4x	0.28+0.3x	0.27+0.2x	0.040.0x	0.150.0x	0.03-0.2x
Asset Turnover	0.000.0x	0.000.0x	0.040.0x	0.030.0x	0.020.0x	0.020.0x	0.010.0x	0.010.0x
FCF Margin	-11023.4%	N/A	-1518.7%	-2059.7%	-860.9%	-1495.6%	-2303.2%	-1507.2%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Lexaria Bioscience Corp. Warrant LEXXW	FY2025	$706K	-$11.9M	N/A	N/A	—
Aspire-Lakewood Holdings, Inc. Warrant ASBPW	FY2025	$6K	N/A	N/A	N/A	—
BriaCell Therapeutics Corp. Warrant BCTXW	FY2025	N/A	-$26.3M	N/A	N/A	—
Dermata Therapeutics, Inc. Warrant DRMAW	FY2025	N/A	-$7.6M	N/A	N/A	—
GeoVax Labs, Inc. Warrants GOVXW	FY2025	$2.5M	-$21.5M	N/A	N/A	51/100
Pasithea Therapeutics Corp. Warrants KTTAW	FY2025	N/A	-$20.4M	N/A	N/A	—

Where Lexaria Bioscience Corp. Warrant Ranks

Frequently Asked Questions

What is Lexaria Bioscience Corp. Warrant's annual revenue?

Lexaria Bioscience Corp. Warrant (LEXXW) reported $706K in total revenue for fiscal year 2025. This represents a 52.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Lexaria Bioscience Corp. Warrant's revenue growing?

Lexaria Bioscience Corp. Warrant (LEXXW) revenue grew by 52.0% year-over-year, from $464K to $706K in fiscal year 2025.

Is Lexaria Bioscience Corp. Warrant profitable?

No, Lexaria Bioscience Corp. Warrant (LEXXW) reported a net income of -$11.9M in fiscal year 2025.

What is Lexaria Bioscience Corp. Warrant's EBITDA?

Lexaria Bioscience Corp. Warrant (LEXXW) had EBITDA of -$11.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Lexaria Bioscience Corp. Warrant's gross margin?

Lexaria Bioscience Corp. Warrant (LEXXW) had a gross margin of 99.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Lexaria Bioscience Corp. Warrant's return on equity (ROE)?

Lexaria Bioscience Corp. Warrant (LEXXW) has a return on equity of -398.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lexaria Bioscience Corp. Warrant's free cash flow?

Lexaria Bioscience Corp. Warrant (LEXXW) recorded an outflow of $10.5M in free cash flow during fiscal year 2025. This represents a -109.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lexaria Bioscience Corp. Warrant's operating cash flow?

Lexaria Bioscience Corp. Warrant (LEXXW) recorded an outflow of $10.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Lexaria Bioscience Corp. Warrant's total assets?

Lexaria Bioscience Corp. Warrant (LEXXW) had $4.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Lexaria Bioscience Corp. Warrant's capital expenditures?

Lexaria Bioscience Corp. Warrant (LEXXW) invested $25K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Lexaria Bioscience Corp. Warrant spend on research and development?

Lexaria Bioscience Corp. Warrant (LEXXW) invested $8.2M in research and development during fiscal year 2025.

How many shares does Lexaria Bioscience Corp. Warrant have outstanding?

Lexaria Bioscience Corp. Warrant (LEXXW) had 20M shares outstanding as of fiscal year 2025.

What is Lexaria Bioscience Corp. Warrant's current ratio?

Lexaria Bioscience Corp. Warrant (LEXXW) had a current ratio of 2.32 as of fiscal year 2025, which is generally considered healthy.

What is Lexaria Bioscience Corp. Warrant's debt-to-equity ratio?

Lexaria Bioscience Corp. Warrant (LEXXW) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lexaria Bioscience Corp. Warrant's return on assets (ROA)?

Lexaria Bioscience Corp. Warrant (LEXXW) had a return on assets of -285.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Lexaria Bioscience Corp. Warrant's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Lexaria Bioscience Corp. Warrant (LEXXW) held $2.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.5M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Lexaria Bioscience Corp. Warrant's Piotroski F-Score?

Lexaria Bioscience Corp. Warrant (LEXXW) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lexaria Bioscience Corp. Warrant's earnings high quality?

Lexaria Bioscience Corp. Warrant (LEXXW) reported a net loss of $11.9M while operations used $10.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.